Placebo arm will receive NaCl 9mg/ml with a dose of 0.2 ml/kg. The placebo dose will be prepared prior to the surgery by a independent nurse. The calculated volume will match the volume of the active durg.

Drug: Placebo

Placebo arm will receive NaCl 9mg/ml with a dose of 0.2 ml/kg. The placebo dose will be prepared prior to the surgery by a independent nurse. The calculated volume will match the volume of the active durg.

Experimental: Erythropoietin

• Active substance: Erythropoietin zeta with the ATC-code: B03XA01. The drug is a Clear colorless solution for injection. The active substance will be diluted with NaCl 9mg/ml to a to a concentration of 2000 U/ml. A dose of 400U/kg will be prepared and marked before the operation. The drug will be administrated after the anesthesia induction and before the start of surgery.

Drug: Erythropoietin zeta

The active drug will be given only once after the anesthesia induction and before the start of surgery. The active drug will be diluted to 2000U/kg and given as a single dose of 400U/kg. The dose will be prepared prior to surgery by a independent nurse.

Other Names:

Active substance: Erythropoietin zeta

Drug brand name: Retacrit®

Manufacturer and Provider: Hospira

ATC-code: B03XA01

Detailed Description:

Acute kidney injury is a common complication after cardiac surgery and is associated with decreased long-term survival.

Several experimental and animal studies have showed cytoprotective, preconditioning and anti-apoptotic effects of high dose erythropoietin. Clinical studies in human have also suggested that high dose erythropoietin has preconditioning effects against injury after ischemia and reperfusion on different organs in human, such as brain, heart, liver, and kidneys.

Administration of Epo in high doses in conjunction with cardiac surgery has shown to be safe with no direct side-effects.

The investigators therefore hypothesize that a preconditioning effect of erythropoietin before cardiac surgery can reduce the level of renal dysfunction after surgery in a group with preoperative renal impairment.

Eligibility

Ages Eligible for Study:

18 Years and older

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

The patient is scheduled for non-emergent CABG surgery.

CyC eGFR or MDRD eGFR < 60 ml/min.

The patient has given his/her written consent to participate

Exclusion Criteria:

The patient has an uncontrolled hypertension.

Hypersensitivity to the active drug.

The patient is pregnant or is a fertile woman (<50 years).

The patient has been treated with Erythropoietin within 4 weeks prior to the surgery.

Preoperative CyC eGFR or MDRD eGFR is < 15, or the patient is treated with dialysis.

The patient has a known malignancy.

The patient is planned for Off-pump CABG surgery.

The patient is included in other ongoing clinical trial. Yes / No

Clinically judgment by the investigator that the patient should not participate in the study.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01423955